Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson filed a Form 13F reporting institutional holdings. The Form 13F Information Table lists 16 entries with a total market value of $652,355,946. The report was signed by Marc Larkins on 05-13-2026 and names one other included manager: Johnson & Johnson Innovation - JJDC, Inc.
JOHNSON & JOHNSON EVP John C. Reed reported routine equity compensation activity involving restricted share units (RSUs) and tax withholding. On May 1, 2026, RSUs covering 25,255 shares of Common Stock vested and were exercised into shares.
To cover taxes due at vesting, 11,002 shares of Common Stock were withheld at a reference price of $229.85 per share. After these transactions, Reed directly owned 24,911 shares of Johnson & Johnson Common Stock. This reflects RSU vesting and related tax withholding, not an open-market purchase or sale.
Johnson & Johnson reported that Vanguard Capital Management beneficially owned 180,631,228 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 180,631,228 shares and sole voting power for 24,025,858 shares.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These DSUs are to be settled in cash when his directorship ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date.
After this award, Woods holds a total of 6,215.094 DSUs, including dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividend. The transaction reflects compensation in the form of deferred, cash-settled, share-linked units rather than an open-market stock purchase or sale.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These DSUs are to be settled in cash when his directorship ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date.
After this award, Woods holds a total of 6,215.094 DSUs, including dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividend. The transaction reflects compensation in the form of deferred, cash-settled, share-linked units rather than an open-market stock purchase or sale.
Johnson & Johnson director Nadja West received a grant of 975 Deferred Share Units (DSUs) on April 23, 2026. These DSUs were acquired under the company’s Amended and Restated Deferred Fee Plan for Directors at a price of $0.00 per unit.
Following this award, West holds a total of 7,730.0491 DSUs. Each DSU will be settled in cash upon the end of her board service, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holding also includes dividend equivalent rights that accrue as the company pays its quarterly dividend.
Johnson & Johnson director Nadja West received a grant of 975 Deferred Share Units (DSUs) on April 23, 2026. These DSUs were acquired under the company’s Amended and Restated Deferred Fee Plan for Directors at a price of $0.00 per unit.
Following this award, West holds a total of 7,730.0491 DSUs. Each DSU will be settled in cash upon the end of her board service, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holding also includes dividend equivalent rights that accrue as the company pays its quarterly dividend.
Johnson & Johnson director Mark A. Weinberger received a grant of 975 Deferred Share Units (DSUs) on Common Stock, reported as a compensation-related acquisition at a price of $0.00 per unit. After this grant, he holds a total of 12,010.408 DSUs directly.
According to the plan terms, these DSUs are to be settled in cash when his service as a director ends, with each DSU valued at the fair market value of one share of Common Stock on the settlement date. The reported holdings also include dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividend.
Johnson & Johnson director Mark A. Weinberger received a grant of 975 Deferred Share Units (DSUs) on Common Stock, reported as a compensation-related acquisition at a price of $0.00 per unit. After this grant, he holds a total of 12,010.408 DSUs directly.
According to the plan terms, these DSUs are to be settled in cash when his service as a director ends, with each DSU valued at the fair market value of one share of Common Stock on the settlement date. The reported holdings also include dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividend.
Pinto Daniel E reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Daniel E. Pinto received a grant of 1,712 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors and are a form of non-cash director compensation.
After this grant, Pinto holds a total of 2,174.069 DSUs. According to the disclosure, these DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The total also reflects dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividends.
Pinto Daniel E reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Daniel E. Pinto received a grant of 1,712 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors and are a form of non-cash director compensation.
After this grant, Pinto holds a total of 2,174.069 DSUs. According to the disclosure, these DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The total also reflects dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividends.
Johnson & Johnson director John G. Morikis received a grant of 1,540 Deferred Share Units (DSUs) as compensation. These DSUs were acquired at a stated price of $0.00 per unit and are tied to Johnson & Johnson common stock for value reference.
According to the plan terms, the DSUs will be settled in cash after Morikis’ service as a director ends, with each unit worth the fair market value of one share of common stock on the settlement date. After this grant, he holds 1,540 DSUs related to this plan.
Johnson & Johnson director John G. Morikis received a grant of 1,540 Deferred Share Units (DSUs) as compensation. These DSUs were acquired at a stated price of $0.00 per unit and are tied to Johnson & Johnson common stock for value reference.
According to the plan terms, the DSUs will be settled in cash after Morikis’ service as a director ends, with each unit worth the fair market value of one share of common stock on the settlement date. After this grant, he holds 1,540 DSUs related to this plan.
McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Mark B. McClellan received a grant of 975 Deferred Share Units (DSUs) tied to the company’s common stock. These DSUs were awarded under the Amended and Restated Deferred Fee Plan for Directors and increase his direct DSU holdings to 21,278.593 units.
The DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one Johnson & Johnson common share on the settlement date. The award also includes dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.
McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Mark B. McClellan received a grant of 975 Deferred Share Units (DSUs) tied to the company’s common stock. These DSUs were awarded under the Amended and Restated Deferred Fee Plan for Directors and increase his direct DSU holdings to 21,278.593 units.
The DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one Johnson & Johnson common share on the settlement date. The award also includes dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.
Joly Hubert reported acquisition or exercise transactions in this Form 4 filing.
JOHNSON & JOHNSON director Hubert Joly received a new equity-based award. On this Form 4, he was granted 975 Deferred Share Units (DSUs) tied to Johnson & Johnson common stock, increasing his DSU holdings to 9,183.605 units.
The DSUs were awarded at a stated price of $0.00 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. According to the disclosure, these DSUs will be settled in cash when Joly’s board service ends, with each DSU representing the fair market value of one share of common stock on the settlement date and including dividend equivalent rights that accrue with the company’s quarterly dividends.
Joly Hubert reported acquisition or exercise transactions in this Form 4 filing.
JOHNSON & JOHNSON director Hubert Joly received a new equity-based award. On this Form 4, he was granted 975 Deferred Share Units (DSUs) tied to Johnson & Johnson common stock, increasing his DSU holdings to 9,183.605 units.
The DSUs were awarded at a stated price of $0.00 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. According to the disclosure, these DSUs will be settled in cash when Joly’s board service ends, with each DSU representing the fair market value of one share of common stock on the settlement date and including dividend equivalent rights that accrue with the company’s quarterly dividends.